Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, reports the Chairman of its associate company, SG Austria, Dr. Walter Gunzburg, participated in multiple private meetings with leading Japanese biotech and pharmaceutical companies following the recent Annual Meeting of the Organisation for Oncology and Translational Research (OOTR), where he was a invited guest speaker.
The meetings took place immediately after his recent "bench to bedside" presentation of data from the clinical trials for the treatment of solid tumors using the company's cutting-edge living cell encapsulation technology. Nuvilex and SG Austria have been actively working to advance the value and use of the live cell encapsulation technology throughout North America and Europe, and are encouraged by the positive response in the Asia-Pacific Rim. Drs. Gunzburg and Salmons have been increasing the number of companies that know about this cutting-edge live cell encapsulation technology and their efforts have been paying off in terms of invitations for in-depth company meetings.
Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, "Japan is well known as an important producer and consumer of advanced medical products and we're excited to report there was keen interest in the use of live cell encapsulation. In addition, we are noting the living cell encapsulation technology is proving to be of great interest to a number of biotech companies developing cell therapies for the treatment of a wide variety of diseases."
About Nuvilex
Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Through substantial effort, aspects of our corporate activities alone and in concert with SG Austria are nearing completion, ultimately providing for a strong future together. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's industry-leading cell and gene therapy expertise and cutting edge, live-cell encapsulation technology.
Safe Harbor Statement
This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
Contacts:
Marmel Communications, LLC
Marlin Molinaro
Ph: (702) 434-8692
mmolinarofc@aol.com
